BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BioNTech (Nasdaq: BNTX) announced that CEO Prof. Ugur Sahin will present an overview at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 9:45 am PST / 12:45 pm ET. A live webcast will be available on the Company's website and will be archived for 30 days. BioNTech is a leader in immunotherapy, focused on innovative therapies for cancer and infectious diseases, leveraging cutting-edge mRNA technology. The Company collaborates with various global pharmaceutical partners to advance its diverse oncology and vaccine pipeline.

Mainz, Germany, December 28, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Prof. Ugur Sahin, M.D., will present a corporate overview and update at the 41^st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PST / 12:45 pm ET.

A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.com/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit www.BioNTech.com.

CONTACT

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

 

FAQ

When will BioNTech present at the J.P. Morgan Healthcare Conference?

BioNTech will present on January 10, 2023, at 9:45 am PST / 12:45 pm ET.

How can I watch BioNTech's presentation at the conference?

You can watch the live webcast on BioNTech's website under the 'Events & Presentations' section.

What is the focus of BioNTech's corporate overview at the conference?

The corporate overview will cover updates on BioNTech's progress in immunotherapy and mRNA vaccine development.

Is there a replay of BioNTech's conference presentation available?

Yes, the presentation will be archived on BioNTech's website for 30 days after the conference.

What key areas does BioNTech specialize in?

BioNTech specializes in immunotherapy, particularly mRNA-based therapies for cancer and infectious diseases.